At Jean-Georges Vongerichten’s new restaurant on the Lower East Side, the menu is supposed to be inspired by the whole city.
NYS Entity Status
NYS Filing Date
NOVEMBER 07, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC REGISTERED LIMITED LIABILITY PARTNERSHIP
2013 - L.M. COHEN & CO. LLP CERTIFIED PUBLIC ACCOUNTANTS
2013 - L.M. COHEN & CO. LLP
Around the Web
- Restaurant Review: Lost in New York at Public Kitchen
By PETE WELLS - Tuesday Oct 10, 2017
- Julius Caesar was much ado over nothing
By Charles Gross - Friday Jun 23, 2017
The Public Theater should get down on its knees and thank Breitbart, Fox News, Bank of America and Delta Airlines. Because of them, the Public’s production of Julius Caesar in Central Park, an...
To view the full story, click the title link.
- New Service Will Certify GDPR Compliance By Vendors
Thursday Sep 14, 2017
The Media Trust has debuted a service for ensuring GDPR compliance.
- Andy Cohen to Replace Kathy Griffin as Anderson Cooper’s ‘New Year’s Eve Live’ Co-Host
By Tony Maglio, provided by
- Wednesday Oct 11, 2017
Andy Cohen is set to replace Kathy Griffin as Anderson Cooper’s “New Year’s Eve Live” co-host on CNN. Maybe just don’t do any gory photoshoots between now and then, Andy — we know Halloween can be tempting.Earlier this year, Griffin was dropped from the annual celebration after doing a photoshoot in which she posed with the decapitated head of Donald Trump. She eventually apologized for the mask stunt, but then later retracted that public mea culpa.Per the comedian, she and Cooper ended their personal friendship after the newsman didn’t come to her defense following the fallout. So, yeah, they probably wouldn’t have shared a kiss at midnight this time around.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]